MX2019011660A - Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). - Google Patents

Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).

Info

Publication number
MX2019011660A
MX2019011660A MX2019011660A MX2019011660A MX2019011660A MX 2019011660 A MX2019011660 A MX 2019011660A MX 2019011660 A MX2019011660 A MX 2019011660A MX 2019011660 A MX2019011660 A MX 2019011660A MX 2019011660 A MX2019011660 A MX 2019011660A
Authority
MX
Mexico
Prior art keywords
erbb
cells
treatment
fusion gene
bispecific antibodies
Prior art date
Application number
MX2019011660A
Other languages
English (en)
Inventor
Throsby Mark
Logtenberg Ton
Anna Wilhelmina Geuijen Cecilia
Andre Baptiste Maussang-Detaille David
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2019011660A publication Critical patent/MX2019011660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al campo de los anticuerpos. En particular, se refiere al campo de los anticuerpos terapéuticos (humanos) para el tratamiento de células positivas para ErbB-2/ErbB-3. Más en particular, se refiere al tratamiento de células que comprenden un gen de fusión NRG1 que comprende al menos una porción del gen NRG1 fusionada a una secuencia desde una ubicación cromosómica diferente.
MX2019011660A 2017-03-31 2018-04-03 Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). MX2019011660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17164292 2017-03-31
PCT/NL2018/050206 WO2018182422A1 (en) 2017-03-31 2018-04-03 Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene

Publications (1)

Publication Number Publication Date
MX2019011660A true MX2019011660A (es) 2019-11-18

Family

ID=58488840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011660A MX2019011660A (es) 2017-03-31 2018-04-03 Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).

Country Status (14)

Country Link
US (3) US11780925B2 (es)
EP (1) EP3600413A1 (es)
JP (1) JP2020511993A (es)
KR (1) KR20190140945A (es)
CN (1) CN110650752A (es)
AU (1) AU2018246873B2 (es)
BR (1) BR112019020508A2 (es)
CA (1) CA3058343A1 (es)
EA (1) EA201992063A1 (es)
IL (2) IL310223A (es)
MX (1) MX2019011660A (es)
PH (1) PH12019550202A1 (es)
SG (1) SG11201908971RA (es)
WO (1) WO2018182422A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
LT3365373T (lt) 2015-10-23 2021-05-25 Merus N.V. Surišančios molekulės, kurios inhibuoja vėžio augimą
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
BR112020002695A2 (pt) 2017-08-09 2020-08-25 Merus N.V. anticorpos que se ligam à egfr e cmet
SG11202009036YA (en) * 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
CN114426578A (zh) * 2019-02-14 2022-05-03 美勒斯公司 结合egfr、her2及her3的结合部分的组合
EP3947440A1 (en) * 2019-03-29 2022-02-09 F. Hoffmann-La Roche AG Method for generating avid-binding multispecific antibodies
GB201913079D0 (en) 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
TW202130664A (zh) * 2019-10-24 2021-08-16 荷蘭商美勒斯公司 用於治療患有ｈｅｒ２及ｈｅｒ３陽性癌症之對象的手段及方法
EP4097261A4 (en) * 2020-01-29 2023-10-18 Board of Regents, The University of Texas System USE OF EGFR/HER2 TYROSINE KINASE INHIBITORS AND/OR HER2/HER3 ANTIBODIES FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
AU2021228225A1 (en) * 2020-02-28 2022-09-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind HER2, and methods of use thereof
CN115843256A (zh) * 2020-10-15 2023-03-24 上海翰森生物医药科技有限公司 抗erbb3抗体或其抗原结合片段及其医药用途
CN117487015A (zh) * 2020-11-04 2024-02-02 美勒斯公司 用于治疗患有erbb3突变阳性癌症的受试者的手段和方法
JP2024509914A (ja) * 2021-03-11 2024-03-05 エレベーション オンコロジー， インコーポレイテッド ニューレグリン１（ｎｒｇ１）遺伝子融合に関連する腫瘍を処置するための抗ｅｒｂｂ３（ｈｅｒ３）モノクローナル抗体の投与量および投与
GB202108449D0 (en) 2021-06-14 2021-07-28 Hummingbird Bioscience Holdings Pte Ltd Cells expressing her3 antigen-binding molecules
EP4396238A1 (en) 2021-09-03 2024-07-10 Cancer Research Technology Limited Treatment and prevention of cancer using her3 antigen-binding molecules
CN114410776B (zh) * 2021-12-21 2023-08-25 南京世和医疗器械有限公司 一种nrg1融合基因的检测方法及试剂盒
WO2024121163A1 (en) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers
WO2024121226A1 (en) 2022-12-07 2024-06-13 Hummingbird Bioscience Pte. Ltd. Combination for treatment and prevention of cancer

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
FI884924A (fi) 1987-10-28 1989-04-29 Oncogen Humanimmuglobulin som producerats med hybrid-dna-teknik.
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
IE922287A1 (en) 1991-07-15 1993-01-27 Wellcome Found Production of antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2237420T5 (es) 1999-04-15 2010-03-03 Crucell Holland B.V. Produccion de proteina recombinante en una celula humana.
US20070111201A1 (en) 2001-04-30 2007-05-17 Benjamin Doranz Reverse transfection of cell arrays for structural and functional analyses of proteins
EP1600510B1 (en) 2001-07-04 2007-03-28 Chromagenics B.V. DNA sequences having anti-repressor activity
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
JP4589914B2 (ja) 2003-01-07 2010-12-01 シムフォゲン・アクティーゼルスカブ 組換え型ポリクローナルタンパク質の製造方法
CA2526284C (en) 2003-06-25 2014-11-18 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
US8124085B2 (en) 2004-05-05 2012-02-28 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
BRPI0511782B8 (pt) 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20070114765A (ko) 2005-02-23 2007-12-04 메리맥 파마슈티컬즈, 인크. 생물학적 활성을 조절하기 위한 이특이성 결합제
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
US8290739B2 (en) 2006-10-20 2012-10-16 Amfit, Inc. Method for determining relative mobility of regions of an object
US8580263B2 (en) 2006-11-21 2013-11-12 The Regents Of The University Of California Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
ES2667863T3 (es) 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
MX2009010611A (es) 2007-04-03 2010-03-26 Micromet Ag Enlazadores biespecificos, especificos para especies.
US7705103B2 (en) 2007-06-22 2010-04-27 3M Innovative Properties Company Polydiorganosiloxane polyoxamide copolymers
SI2173379T1 (sl) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
US8536310B2 (en) 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
EP2235536A4 (en) 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2 DIAGNOSTIC METHODS
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
JP5530367B2 (ja) 2008-02-05 2014-06-25 ザイムワークス，インコーポレイテッド 分子動力学を使用してタンパク質またはその他のバイオポリマー中の相関残基を決定するための方法
SI3456190T1 (sl) 2008-06-27 2022-06-30 Merus N.V. Transgena mišja živali, ki proizvaja protitelesa
BRPI0918768B1 (pt) 2008-08-29 2022-08-30 Symphogen A/S Composições de anticorpo recombinante de antireceptor do fator de crescimento epidérmico
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
SG10201408392PA (en) 2009-01-15 2015-01-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
SG172977A1 (en) 2009-01-26 2011-08-29 Genmab As Methods for producing mixtures of antibodies
CN104447995A (zh) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EP2445936A1 (en) 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CN103002912A (zh) 2009-08-21 2013-03-27 梅里麦克制药股份有限公司 针对ErbB3的胞外结构域的抗体及其用途
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5960598B2 (ja) 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PT2505654T (pt) 2010-02-08 2016-11-18 Regeneron Pharma Rato de cadeia leve comum
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
PT2606064E (pt) 2010-08-16 2015-06-08 Novimmune Sa Processos para a geração de anticorpos poliespecíficos e polivalentes
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
MX2013009732A (es) 2011-02-24 2013-12-06 Merrimack Pharmaceuticals Inc Terapias de combinacion comprendiendo agentes anti-erbb3.
AU2012229147B2 (en) 2011-03-11 2015-12-24 Merrimack Pharmaceuticals, Inc. Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
JP2014509593A (ja) 2011-03-15 2014-04-21 メリマック ファーマシューティカルズ インコーポレーティッド ＥｒｂＢ経路阻害剤に対する耐性の克服
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
PT2707391T (pt) 2011-05-13 2018-02-06 Inserm Institut National De La Santa© Et De La Rech Ma©Dicale Anticorpos contra her3
CN103781800A (zh) 2011-06-20 2014-05-07 协和发酵麒麟株式会社 抗erbB3抗体
US9567827B2 (en) 2013-07-15 2017-02-14 Downhole Technology, Llc Downhole tool and method of use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
SG11201400150TA (en) 2011-09-30 2014-03-28 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
BR112014012539B1 (pt) 2011-11-23 2022-12-20 Medimmune, Llc Anticorpo que se liga especificamente a her3, composição compreendendo o mesmo, e usos do anticorpo
CN104159924B (zh) 2011-12-05 2018-03-16 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
MX2014006731A (es) 2011-12-05 2015-06-04 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3) dirigidos al dominio iii y al dominio iv del her3.
WO2013134686A1 (en) 2012-03-09 2013-09-12 Promega Corporation pH SENSORS
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
JP6471095B2 (ja) 2012-09-27 2019-02-20 メルス ナムローゼ フェンノートシャップ Ｔ細胞エンゲージャーとしての二重特異性ＩｇＧ抗体
US10093740B2 (en) 2012-10-15 2018-10-09 Universitat Zurich Bispecific HER2 ligands for cancer therapy
HUE041499T2 (hu) 2012-11-21 2019-05-28 Janssen Biotech Inc Bispecifikus EGFR/C-MET-ellenanyagok
CA2899353A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
CA2900955A1 (en) 2013-03-14 2014-10-02 Oncomed Pharmaceuticals, Inc. Met-binding agents and uses thereof
WO2014165855A1 (en) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US10208354B2 (en) * 2013-08-07 2019-02-19 Universität Zu Köln NRG1 fusion genes in cancer
US9551208B2 (en) 2013-08-26 2017-01-24 Halliburton Energy Services, Inc. Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation
WO2015066543A1 (en) 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
DK3110849T3 (da) 2014-02-28 2020-11-23 Merus Nv Antistof, der binder erbb-2 og erbb-3
AU2015223566B2 (en) 2014-02-28 2020-10-08 Merus N.V. Antibodies that bind EGFR and ErbB3
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
WO2016077734A2 (en) 2014-11-14 2016-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
LT3365373T (lt) 2015-10-23 2021-05-25 Merus N.V. Surišančios molekulės, kurios inhibuoja vėžio augimą
EA201992063A1 (ru) 2017-03-31 2020-03-26 Мерус Н.В. СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
EP3600411A1 (en) 2017-03-31 2020-02-05 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
JP7296891B2 (ja) 2017-05-17 2023-06-23 メルス ナムローゼ フェンノートシャップ 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
BR112020002695A2 (pt) 2017-08-09 2020-08-25 Merus N.V. anticorpos que se ligam à egfr e cmet

Also Published As

Publication number Publication date
BR112019020508A2 (pt) 2020-08-04
SG11201908971RA (en) 2019-10-30
JP2020511993A (ja) 2020-04-23
EP3600413A1 (en) 2020-02-05
AU2018246873B2 (en) 2021-05-06
US20240199747A1 (en) 2024-06-20
CA3058343A1 (en) 2018-10-04
IL269656B1 (en) 2024-02-01
US20240182587A1 (en) 2024-06-06
KR20190140945A (ko) 2019-12-20
IL310223A (en) 2024-03-01
IL269656A (en) 2019-11-28
WO2018182422A8 (en) 2019-10-31
AU2018246873A1 (en) 2019-10-17
WO2018182422A1 (en) 2018-10-04
CN110650752A (zh) 2020-01-03
US11780925B2 (en) 2023-10-10
IL269656B2 (en) 2024-06-01
PH12019550202A1 (en) 2020-07-13
US20200102393A1 (en) 2020-04-02
EA201992063A1 (ru) 2020-03-26

Similar Documents

Publication Publication Date Title
PH12019550202A1 (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2019011148A (es) Metodos de tratamiento.
NZ738008A (en) Tigit-binding agents and uses thereof
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
TN2016000559A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2017004526A (es) Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
WO2017049038A3 (en) Anti-cd115 antibodies
MX2016011114A (es) Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.
MX2023003519A (es) Anticuerpo anti-semaforina 4d humano.
IL281441A (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
MX2016011295A (es) Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2.
MX2017011937A (es) Antagonistas del receptor de nk-3 para el tratamiento terapeutico o cosmetico de la grasa corporal excesiva.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
IL272397A (en) Optimal peptides targeting human neurons and their use in image-guided analysis, diagnostics and therapeutic administration
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2021003262A (es) Metodos de tratamiento.